The Difference an Antiviral Pharmacologist Makes

Most writing about antiviral medication starts from the prescribing information and works outward. Richard’s writing starts from the molecule and works toward the patient. He spent the early part of his career at the laboratory bench characterizing how ganciclovir actually inhibits cytomegalovirus DNA replication — work that produced a 1988 mechanism paper in Reviews of Infectious Diseases still cited nearly four decades later in contemporary pharmacology reviews and structure-based antiviral drug design.

That bench grounding changes what readers get. When Richard explains how a nucleoside analogue terminates viral DNA synthesis, why a licensed generic is bioequivalent to a branded product, or what a manufacturing-quality standard actually guarantees, the explanation rests on direct understanding of viral polymerase inhibition rather than restated package-insert language. For SunnyPharma’s HIV cost-access and HCV treatment cost content, that depth lets him write about mechanism, generic equivalence, and treatment-decision logic with the precision the questions deserve.

From the Bench to Publication Practice

Richard earned his PhD in pharmacology with a focus on antiviral drug mechanism, working on the herpesvirus family during the years when the AIDS epidemic was redirecting much of the antiviral research field. His peer-reviewed publications from that period include the foundational ganciclovir mechanism paper with Thomas Matthews (Reviews of Infectious Diseases, 1988), in vitro and in vivo activity studies of ganciclovir phosphate derivatives against cytomegalovirus (Antiviral Research, 1986, and Antimicrobial Agents and Chemotherapy, 1985), and the discovery of jasplakinolide as a new class of antifungal agent from a marine sponge (Antimicrobial Agents and Chemotherapy, 1988). This body of work was conducted within the antimicrobial chemotherapy research program at Syntex Research.

Following his bench career, Richard moved into medical communications — the specialized writing discipline that converts clinical trial data, regulatory filings, and congress presentations into peer-reviewed manuscripts and patient-facing education. He earned his MBA to understand the commercial side of pharmaceutical publication and his CMPP credential through the International Society for Medical Publication Professionals (ISMPP), the body that defines ethical standards for medical publication practice. Today he works independently as a medical writer, consultant, and strategic planner, with a focus on disease-area medical communications across the pharmaceutical and digital-health space.

For SunnyPharma he focuses on the antiviral and treatment-cost content where his pharmacology background does the most work: explaining how antiretroviral and direct-acting antiviral regimens function, walking readers through what licensed generics actually contain, and translating cure and suppression data from the clinical trial literature into language patients can apply to their own decisions.

What Richard Contributes to SunnyPharma

Selected Peer-Reviewed Research

Richard authored or co-authored peer-reviewed antiviral pharmacology research that remains in active citation across modern clinical pharmacology, virology, and structure-based drug-design literature. These works are verifiable through PubMed and the primary journals:

Writing Standards & Editorial Transparency

All content authored by Richard Boehme for SunnyPharma is developed in accordance with ICMJE (International Committee of Medical Journal Editors) recommendations, GPP (Good Publication Practice) guidelines, and the ethical standards of the International Society for Medical Publication Professionals (ISMPP). Richard applies the same regulatory-grade publication discipline he brings to peer-reviewed manuscript development, ensuring every SunnyPharma article is mechanistically accurate, primary-source referenced, and appropriate for a cost-burdened patient audience.

Credentials & Background

Areas of Expertise

Why Richard Writes for SunnyPharma

Richard’s career has spanned the full path of an antiviral medication — from molecular characterization at the bench, to clinical trial publication, to the regulatory and commercial decisions that determine whether a medication reaches a patient at a price they can afford. SunnyPharma’s mission sits at the patient-facing end of that path. The bridge from mechanism to access is exactly the bridge his career was built on, and the cost-burdened patient is exactly the reader his pharmacology training was always meant to serve.